about
Side effects of yttrium-90 radioembolizationRadiologic-pathologic correlation of hepatocellular carcinoma treated with chemoembolizationChemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort.Chemoembolization and radioembolization for metastatic disease to the liver: available data and future studies.Perfusion reduction at transcatheter intraarterial perfusion MR imaging: a promising intraprocedural biomarker to predict transplant-free survival during chemoembolization of hepatocellular carcinomaRole of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlationImaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma.Research reporting standards for radioembolization of hepatic malignancies.Chemoembolization endpoints: effect on survival among patients with hepatocellular carcinoma.Intraprocedural transcatheter intra-arterial perfusion MRI as a predictor of tumor response to chemoembolization for hepatocellular carcinomaRadioembolization for primary and metastatic liver cancer.Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomesExtrahepatic metastases occur in a minority of hepatocellular carcinoma patients treated with locoregional therapies: analyzing patterns of progression in 285 patients.Radioembolization for hepatocellular carcinoma with portal vein thrombosis: impact of liver function on systemic treatment options at disease progression.Radiologic findings following Y90 radioembolization for primary liver malignancies.Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection.Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review.Yttrium-90 radioembolization in the management of liver malignancies.Yttrium 90 microspheres for the treatment of hepatocellular carcinoma.Making the Case: Intra-arterial Therapy for Less Common Metastases.New Developments in Interventional Oncology: Liver Metastases From Colorectal Cancer.Radioembolization of Hepatic Malignancies: Background, Quality Improvement Guidelines, and Future Directions.Surveillance, anticoagulation, or filter in calf vein thrombosis.Long-Term Hepatotoxicity of Yttrium-90 Radioembolization as Treatment of Metastatic Neuroendocrine Tumor to the Liver.Interventional radiology in the management of the liver transplant patient.Clinical outcomes of Y90 radioembolization for recurrent hepatocellular carcinoma following curative resection.Improving inferior vena cava filter retrieval rates: impact of a dedicated inferior vena cava filter clinic.Sustained safety and efficacy of extended-shelf-life (90)Y glass microspheres: long-term follow-up in a 134-patient cohort.Y90 Radioembolization for Locally Advanced Hepatocellular Carcinoma with Portal Vein Thrombosis: Long-Term Outcomes in a 185-Patient Cohort.Institutional Decision to Adopt Y90 as Primary Treatment for HCC Informed by a 1,000-patient 15-year Experience.Radioembolization for hepatocellular carcinoma: Statistical confirmation of improved survival in responders by landmark analyses.Pictorial essay: imaging findings following Y90 radiation segmentectomy for hepatocellular carcinoma.Immuno-oncology and Its Opportunities for Interventional Radiologists: Immune Checkpoint Inhibition and Potential Synergies with Interventional Oncology Procedures.Pretransplantation Portal Vein Recanalization and Transjugular Intrahepatic Portosystemic Shunt Creation for Chronic Portal Vein Thrombosis: Final Analysis of a 61-Patient Cohort.Pretransplant Intra-arterial Liver-Directed Therapy Does Not Increase the Risk of Hepatic Arterial Complications in Liver Transplantation: A Single-Center 10-Year Experience.Perceptions of Quality in Interventional Oncology.Survival Analysis of Advanced HCC Treated with Radioembolization: Comparing Impact of Clinical Performance Status Versus Vascular Invasion/Metastases.Comparative study of post-transplant outcomes in hepatocellular carcinoma patients treated with chemoembolization or radioembolization.Indicators of Lung Shunt Fraction Determined by Technetium-99 m Macroaggregated Albumin in Patients with Hepatocellular Carcinoma.Covered stent use after subclavian artery and vein injuries in the setting of vascular Ehlers-Danlos.
P50
Q26821887-E909FF1B-BE87-4478-B6D2-61D8EFC14369Q34065098-0617C1F1-D4A0-425B-A9CB-CD0E6118C42AQ34168811-1DC7323A-8466-4496-A618-B76AB206897DQ34330617-1DBA410F-28BA-4145-B96B-9746C53F7224Q34681150-493CC9E7-7E19-476F-96D8-5AB3B1129BB5Q34982068-5B78CB87-B94C-4324-9A26-0751936B8222Q35051942-5A133779-EC43-485F-9EF2-1ED6608757DFQ35111887-089AFB9D-32DA-47CE-871F-8816A2454843Q35168279-4E5E87B7-840D-4030-8DAF-70EBCB41E3EEQ35203257-BC6FF1AB-5E06-4963-96A2-71D7746824BEQ35564038-3F53C775-4AE1-43F3-9854-4E093DE9CC63Q35815482-E4077B77-3F1C-44AB-B2A5-11B0CC831A1EQ35877902-3663A2D2-F460-4B77-BA3D-D872FD0D0DE9Q36481071-0EFF6065-00FD-4E2F-8439-56C8E98AA960Q37262855-88A70D62-B26B-4BE3-BF49-4FB21E71AAA8Q37376714-783831C4-EDE7-4EC7-A651-BF77D6E27C6DQ37565869-50E77219-5371-42CB-ACE9-FD5557D731D1Q37759927-760451DB-CCC4-46E9-B955-3BE0D9E1B983Q38039874-2F184F57-E1E0-4B2F-9EEB-9496F67EE075Q38745186-4CE5990D-B05E-42EE-BE22-AE6E5F4A75C4Q38792621-ABB4F3A3-B3D0-4DCE-BD7A-8593E571AEA0Q38796291-6F23C616-D625-49B6-A1C1-F792CEE27188Q39092843-B17ED9D5-E345-4850-978B-408A64955E3DQ39412258-568933CD-444D-4815-8231-A1CD5B9D3C11Q39456580-CD3D3ADD-FCAF-409D-9A7E-6FDCE2F42B49Q40091767-B5F62F70-ED2D-44A4-9BBD-ABD8B3AF8911Q44473889-E4EABBA4-B122-4B12-A956-1854E2298EBFQ46151344-9FF7D188-D947-4A64-A9D4-6A2F0730EC03Q47347973-06CCF830-EB53-4432-BE33-BE9BA9FB36DAQ47384456-D52A41AC-4326-400C-9E10-E1141C178ABBQ48193183-33BD8373-C505-4DD5-9162-232A38FA61A5Q48285755-5C8B4813-B593-4868-8D53-1E395F660C6EQ50083741-BA1DBB02-E904-440A-BC27-182D263F2383Q50098939-32E321E3-21DF-4DCA-BA17-85E38A9D2B60Q50125448-82FAC669-4A8F-4340-BBA2-318E3C02487EQ50207626-61A4F4CE-8679-4293-81A4-96444AF2742AQ50209684-A5919C8D-198C-4FFF-A0A9-91BE46434211Q50550624-C02F16A6-A2FB-4DF5-86A7-1CBD97490C9BQ52893237-2B763EEC-BCA7-44D3-93BD-7FBA601999B9Q53199798-C591132C-8F42-4EE7-AD51-FAF6E04C5BE8
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ahsun Riaz
@ast
Ahsun Riaz
@en
Ahsun Riaz
@es
Ahsun Riaz
@nl
type
label
Ahsun Riaz
@ast
Ahsun Riaz
@en
Ahsun Riaz
@es
Ahsun Riaz
@nl
prefLabel
Ahsun Riaz
@ast
Ahsun Riaz
@en
Ahsun Riaz
@es
Ahsun Riaz
@nl
P106
P1153
24759536300
P31
P496
0000-0002-1544-4494